Avelo wins €1.5 million Eurostars Grant
Avelo is now part of a consortium of three companies, including VIVOLTA from the Netherlands and BLINK from Germany.
News
What a year for core sensing!
Within one year since our closing in 2022 with OCCIDENT as lead investor, core sensing can show impressive successes.
Successful Exit adivo
We are excited to announce the successful exit of our portfolio company adivo, which we have supported from the very beginning as one of the first investors.
New Investment in ReCatalyst
OCCIDENT is expanding its industrial tech portfolio by investing in an innovative fuel cell catalyst technology from Slovenia.
Initial Investment in EBAMed
OCCIDENT invests in the Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias using proton therapy.
Successful Exit Lunaphore
The company announced that it has entered into an agreement to be acquired by Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company.
Thermosome receives important grant
Thermosome receives a € 1.3 million grant from the Innovative Health Initiative and becomes part of IMAGIO consortium.
Positive Interim Analysis
Good news and great hope for all patients suffering from chronic neuropathic pain comes from our portfolio company Algiax Pharmaceuticals.
First Patient In
The Munich-based drug development company Thermosome, specialized in targeted tumor therapies, announced that the first patient has been dosed.